IL2 and neoplasm: Compared to the targeted delivery of antigens, in situ vaccination offers neoantigens that are expressed only in the tumor site, which would provide less systemic toxicity and greater immunogenicity.[93] The in situ vaccination provides tumor‐specific antigens and induces tumor cell death by chemotherapy, oncolytic virus, etc.; or introduces immune activators (interleukins (IL) like IL‐2, IL‐7, stimulator of interferon gene (STING) agonists, etc.)to activate local innate immunity and adaptability of tumor immunity.